33142-21-1

Basic information

• Product Name: ethyl (chloroformyl)acetate
• Synonyms: 2-Chloro-3-oxopropanoic acid ethyl ester;2-Chloro-3-oxopropionic acid ethyl ester;Ethyl 2-Chloro-3-oxopropanoate;Propanoic acid, 2-chloro-3-oxo-, ethyl ester;Ethyl α-ForMyl-α-chloroacetate;Ethyl 2-chloro-2-formylethanoate, Ethyl 2-chloro-3-oxopropionate;Ethyl 2-chloro-3-oxopropanoate, tech;2-chloro-3-oxopropanoate
• CAS NO: 33142-21-1
• Molecular Formula: C₅H₇ClO₃
• Molecular Weight: 150.56
• EINECS: 251-390-6
• Product Categories: Miscellaneous Reagents
• Mol File: 33142-21-1.mol
• Article Data: 43

Chemical Properties

• Melting Point: 88-90 °C(Solv: benzene (71-43-2))
• Boiling Point: 172.5°Cat760mmHg
• Flash Point: 68.2°C
• Appearance: /
• Density: 1.217 g/cm³
• Vapor Pressure: 1.34mmHg at 25°C
• Refractive Index: 1.431
• Storage Temp.: Hygroscopic, -20°C Freezer, Under Inert Atmosphere
• PKA: 4.09±0.29(Predicted)
• Stability: Store FROZEN
• CAS DataBase Reference: ethyl (chloroformyl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl (chloroformyl)acetate(33142-21-1)
• EPA Substance Registry System: ethyl (chloroformyl)acetate(33142-21-1)

Safety Data

• Hazardous Substances Data: 33142-21-1(Hazardous Substances Data)

Usage

Chemical Properties

Thick Oil

Uses

Material that was assayed to be approximately 80% pure was diluted to 5% in benzene.

InChI:InChI=1/C5H7ClO3/c1-2-9-5(8)3-4(6)7/h2-3H2,1H3

Upstream product

• 1001-26-9 ethyl 3-ethoxyacrylate 
• 64-17-5 ethanol 
• 105-39-5 chloroacetic acid ethyl ester 
• 109-94-4 formic acid ethyl ester 
• 1027194-45-1 potassium (1E)-2-chioro-3-ethoxy-3-oxoprop-1-en-1-olate 

Downstream Products

• 99853-81-3 ethoxycarbonylchloroacetaldehyde 2,4-dinitrophenylhydrazone 
• 18227-18-4 benzimidazole hydrochloride 
• 105-39-5 chloroacetic acid ethyl ester 
• 113853-16-0 2-amino-oxazole-5-carboxylic acid ethyl ester 
• 1095823-35-0 C₁₅H₁₆N₂O₄S 
• 1134327-98-2 7-bromoimidazo[1,2-a]pyridin-3-carboxylate ethyl ester 
• 1313410-31-9 ethyl 6-cyanoimidazo[1,2-a]pyridine-3-carboxylate 
• 1313408-99-9 ethyl 7-fluoroimidazo[1,2-a] pyridine-3-carboxylate 
• 1296201-68-7 7-chloro-imidazo[1,2-a]pyridine-3-carboxylic acid ethyl ester 
• 1220631-47-9 6-chloro-8-(cyclopropyl(4-methoxybenzyl)amino)imidazo[1,2-b]pyridazine-3-carbonitrile 
• 1027706-89-3 ethyl 2-[4-({(tert-butoxycarbonyl)[(1R)-1-(1-naphthyl)ethyl]amino}methyl)-3-(3-fluorophenyl)piperidin-1-yl]-1,3-thiazole-5-carboxylate 
• 1095824-45-5 C₁₃H₁₁F₃N₂O₂S 
• 1095824-37-5 C₁₇H₂₀N₂O₄S 
• 945226-82-4 ethyl 2-(2-chloro-5-(trifluoromethyl)phenyl)thiazole-5-carboxylate 

Relevant articles and documents

Thiazole derivative and synthesis method thereof

The invention belongs to the technical field of organic synthesis, particularly relates to a thiazole derivative and a synthetic method thereof, and particularly relates to a thiazole derivative (Z)-4-((2-(2-(2-(2,5-dimethoxyphenyl)-thiazole-5-yl)-ethylimino)(phenyl)methyl)-1,3-benzenediol and a synthetic method thereof. The synthesis method provided by the invention comprises the following steps:by taking 2,5-dimethoxybenzamide and ethyl 2-chloroacetate as raw materials, carrying out six reaction steps of carbonyl sulfide reaction, substitution, cyclization, substitution, chlorination, cyanidation, amidation, hydrolysis and substitution reaction to prepare the (Z)-4-((2-(2-(2-(2,5-dimethoxyphenyl)-thiazole-5-yl)-ethylimino)(phenyl)methyl)-1,3-benzenediol. According to the invention, an efficient synthesis method is provided for the synthesis of the thiazole derivative.

COMPOUNDS CONTAINING POLYSUBSTITUTED BENZO[D][1,3]OXATHIOLE, BENZO[D][1,3]OXATHIOLE 3-OXIDE OR BENZO[D][1,3]OXATHIOLE 3,3-DIOXIDE AND METHODS/USES THEREOF AS AGONISTS OF G PROTEIN-COUPLED RECEPTOR 119

There are provided compounds having formula (I), in which: X1 and X2 are selected from certain combinations of O, S, SO and SO2; X3 is selected from CH, CF and N; X4 is selected from CH and N; X6, X6' and X6'' are selected from H, halogen, and certain alkyl, haloalkyl, alkoxy, hydroxyalkyl, and amide groups; X7 and X7' are selected from H, halogen, and certain alkyl, haloalkyl, alkoxy, hydroxyalkyl, aminoalkyl and amide groups, or both X7 and X7' together form a cycloalkyl or heterocycle; and A is selected from certain optionally substituted, alkoxy, piperazinyl and pyrrolidinyl groups. Also provided are compositions comprising these compounds, as well as uses/methods related thereto, including treatment of diseases and conditions associated with GPR119 dysregulation, Type 2 diabetes mellitus, and related metabolic disorders. (I)

FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR

The present invention discloses a five-membered heterocyclic amide WNT pathway inhibitor, which belongs to a compound that regulates the activity of a Wnt signaling pathway, and provides a method for preparing such a compound, and the use of such a compound in preparing a medicament that antagonizes the Wnt signaling pathway. The five-membered heterocyclic amide WNT pathway inhibitor provided by the invention has a remarkable anti-tumor activity based on a target-based rational drug design of, and can be used for the development of a new generation of Wnt pathway inhibitors, and has a great clinical application value and considerable market potential.